Information On alectinib
  • Blog
  • About
  • Contact

Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.

2/3/2015

0 Comments

 
AbstractCrizotinib is a potent and specific small-molecule inhibitor of both anaplastic lymphoma kinase (ALK) and c-MET tyrosine kinases, and patients with ALK rearrangement tumor benefit from crizotinib treatment; however, its penetration into calculated cerebrospinal fluid (CSF) is considered to be poor. Alectinib is a highly selective, next-generation ALK inhibitor, and both preclinical and clinical studies have indicated that alectinib is also effective in crizotinib-resistant tumors. A recent in vitro study demonstrated significant antitumor activity of alectinib for brain metastases using mouse models of ALK-positive non-small-cell lung cancer. In this paper, we report a first case alectinib was highly effective against brain metastases refractory to crizotinib. Further investigation of alectinib in this setting would be particularly valuabl


Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan
0 Comments



Leave a Reply.

    Resource

    This site is a collection of resources on Alectinib.

    Archives

    February 2015

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • Blog
  • About
  • Contact